Cell line · CVCL_5160
Papers34
1 to 20 of 34
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Systematic Targeting of Protein Complexes with Molecular COUPLrs. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integration and validation of complementary ex vivo assays for functional precision oncology. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors. | Genome Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Clinical Characteristics and Spatial Transcriptome Analysis of Non-Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis. | Cancer Metab | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| AXL and SHC1 confer crizotinib resistance in patient-derived xenograft model of ALK-driven lung cancer. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 37994369 | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. | Nat Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Loss of spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitors. | 2022 | Cellosaurus cites it | DOI | ||
| A MET-PTPRK kinase-phosphatase rheostat controls ZNRF3 and Wnt signaling. | Elife | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. | Cancers (Basel) | 2021 | Its Methods give the RRID and name the line | PubMed | |
| RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. | Cell Chem Biol | 2020 | Its Methods give the RRID and name the line | PubMed | |
| From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. | J Cell Biochem | 2020 | Cellosaurus cites it | PubMed | |
| Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. | Int J Cancer | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_5160/papers